Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Faron Pharmaceuticals, H1'26

By Inderes8/26/2026, 12:00 PM
Faron Pharmaceuticals

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Juho Jalkanen
00:04 - 12:08

Hello everyone. Welcome to the Faron Pharmaceuticals Oy Half-Year Report webcast. Apologies for the technical issues in the beginning, but I think we're now up and running and happy to be here with you. Next slide please. As a biotech, we will be making forward-looking statements. So, our standard disclaimer. Next slide please. For today's agenda, I will be taking you through the past key events and also the future outlook. Then our Chief Financial Officer, Jurriaan Dekkers, will be presenting the actual financial results, followed by a Q&A session. Next slide please. Okay, let's go to the key events of the first half. Next slide, please. First and foremost, there may be some newcomers to the story. So. A short introduction to Faron Pharmaceuticals Oy and high-risk myelodysplastic syndrome. First of all, Faron Pharmaceuticals Oy is a clinical-stage immunotherapy company with proven efficacy in phase two, demonstrating that we can overcome treatment resistance in some very difficult cancers. Our lead focus is on high-risk myelodysplastic syndrome, or HR MDS. It is a lethal form of leukemia causing severe anemia, severe infections and bleeding. And there have been no new treatments for the past 20 years. It is currently treated with a chemotherapy-like regimen named hypomethylating agents. The problem with hypomethylating agents is that the majority do not get a proper response, and eventually, basically everybody relapses and there is no approved second-line therapy. This is an orphan indication, but the market opportunity is significant. With 40,000 new patients each year in the US and main EU countries. Faron Pharmaceuticals' bexmarilimab is a first-in-class anti-Clever-1 antibody. It is one of the rare drugs that has actually shown that it can improve cancer cell killing, while also inducing the production of healthy blood cells in the bone marrow. And this is key for deep and durable responses and sustainable benefit for patients. So let's have a look at what this drug does. Next slide please. Again, this is a first-in-class anti-Clever-1 antibody. Number one, we activate the immune system through activating monocytes and macrophages. And now, number two: Myelodysplastic syndrome is a cancer of the macrophage population. So all the cancer cells, known as blasts, are Clever-1 positive. So in the context of myelodysplastic syndrome, we're not just activating the immune system, we're also depriving cancer of its main source of protection. And this is likely why we are seeing such good results. We believe we are one of the first drugs to tackle the core biology of myelodysplastic syndrome, which makes it such a difficult disease to treat. Next slide please. So, what has recently happened? We have completed a phase one/two open-label study. Follow-up data has continued to come in, and it has been strong, confirming sustainable benefit for patients. Meanwhile, in the area of high-risk myelodysplastic syndrome, there have unfortunately been a lot of phase three failures. But these come with important learnings which we have now taken into consideration, and they have guided us to put together a Phase 2b study in frontline, HR MDS. Based on that, we have completed one of the biggest financial rounds in Finland for biotechs, 40 million raised through a rights offering, and now we are funded to deliver this phase 2b readout. But on top of that, we will also be delivering phase 1/2 data in a number of solid tumor indications. So truly exciting times ahead. Next slide please. I would like to take this moment to look at the landscape of high-risk myelodysplastic syndrome. The absolute vacuum of new treatment options has brought a lot of pharma companies into this area. So, there is actually a lot of development ongoing. It is primarily early stage. So, we have now evolved as one of the leading candidates in this space, and especially a leading candidate when it comes to disease-modifying agents. What we are showing here on the screen is that some of these attempts still rely on targets that have unfortunately failed in this space, such as CD47, BCL-2 inhibitors, and also kinase inhibitors. But there is a nice fleet of new immunomodulating agents coming to this area, for example, a Galectin-9 inhibitor or a PI3K gamma inhibitor. So I would say now, finally, the field of MDS has understood that we cannot continue giving toxic cytopenic drugs to these patients. We need something truly disease-modifying. And we are leading this new era. Next slide please. And what really makes our drug, Bexmarilimab, different—and I would say special—is the mode of action we have demonstrated. And then the safety profile that comes with the mode of action. We are not a cytotoxic agent causing anemia and neutropenia. Actually, it looks like we are making it better. So here in this slide in gray, you can see what is expected from a safety profile for the market-leading hypomethylating agent, azacitidine. But when we add bexmarilimab to azacitidine, we are not actually increasing these safety issues. We are actually making them better because we are, again, one of the rare, possibly only drugs that improves cancer cell killing while also inducing the production of healthy blood cells. Next slide please. So that was the safety and this is the efficacy. What are we looking at here in the front line where patients receive azacitidine. Also, in the first-line setting, one can historically expect a 16% to 17% complete remission rate, and in recent trials, up to 20%. And that is ultimately what you want to achieve for these patients. Complete remission means the cancer is gone and blood counts are back to normal. What we have seen in our open-label phase 1/2 trial is a 45% complete remission (CR) rate, which is outstanding. Still, survival is pretty mature in the front-line setting, but we have just recently reported the first data cut, and we will be presenting those in upcoming medical conferences now in the last lines and in the relapsed refractory setting where nothing seems to work. Salvage treatment usually only provides 5 to 6 months of median survival. We are expecting to double that. So again sustainable benefit for patients. Next slide please. So we are entering late-stage development. We have further strengthened our team during H1. Chief Technical Officer Mr. Heikki Jouttijärvi has started with decades of experience bringing drugs to market from a supply chain and manufacturing perspective. Just as important as the clinical trials is the manufacturing of the drug and preparing it for marketing approval. We have partnered with Parexel, a world-leading global contract research organization, to deliver the Phase 2b study. We are very happy with this partnership and it has gotten off to a good start. Then on the business development side, we have further strengthened our team with George Golumbeski joining our board. He brings decades of experience from business development across the industry. We are extremely happy with our team. Next slide please. So recently, what is now coming up? Then, we have announced that the BLAZE study in checkpoint refractory lung and melanoma has gained regulatory approval. Also, the BEXERA study in soft tissue sarcoma has gained regulatory approval. The FINPROVE study in breast cancer will not be proceeding. It will require a standalone study, and we are focusing our resources on our main myelodysplastic syndrome program. Instead of putting together a standalone study for breast cancer, we are focusing on our AML study. BEAM-X is also progressing, and currently in protocol development is the further relapsed/refractory myelodysplastic syndrome study with the City of Hope, utilizing oral hypomethylating agents, the newcomer to the area. So, a rather vast pipeline is producing a lot of new data for such a small company. Next slide please. What can our audience and investors look forward to for H2? As I mentioned, we just completed the first data cut for the survival readout in the frontline high-risk MDS population. The data is trending well. We will report further follow-up data in upcoming conferences. And this is why this data cut was performed. Also, at an upcoming major conference, we will be reporting more mature data from the first-in-human solid tumor trial and providing updates on how our trials are progressing in solid tumors. So the scientific foundation of Clever-1 continues to strengthen and broaden during the second half. Next slide please. So what can one anticipate further from a news flow? There will now be a series of first patient-in announcements in H2 for a number of these trials. There will be further follow-up data from our existing trials. But then comes the most exciting year, 2027, when a lot of this data will be coming out from these trials. So very exciting times ahead. We have worked extremely hard during H1 to get these trials started. They are starting. I couldn't be more excited. Next slide please. So, next we will give the floor to our Chief Financial Officer to talk about the financial results.

Heikki Jouttijärvi
12:09 - 15:21

Thank you. I will present our financial results for the first half of 2026. The first six months of the year have been transformational for Faron Pharmaceuticals Oy. From a financial perspective, we significantly strengthened our balance sheet through the successful completion of a fully covered rights offering, providing the resources needed to execute our clinical development strategy and advance into our next major milestones. Our financial performance reflects continued disciplined cost management while maintaining strong focus on value-generating clinical activities. Most importantly, we now have the funding necessary to support the phase two BEXERA clinical trial and also support our efforts to reach key data readouts expected in 2027. Next slide please. During the first half of 2026, we substantially strengthened our financial position through the successful completion of our rights offering. The transaction generated gross proceeds of approximately €40 million and net proceeds of approximately €32.8 million. As a result, our cash position increased to €32 million at the end of June 2026, compared with €13.5 million at the same time last year. Importantly, we are now funded through the expected Phase 2 BEXERA readout in 2027 and several other important milestones across our development program. Operating loss for the period was €11.1 million, broadly in line with the €11.8 million operating loss reported in the first half of 2025. This reflects our continuous focus on responsible capital allocation, advancing our clinical development program. Our balance sheet has also improved significantly, with net assets of €11.6 million at the end of June 2026, compared with negative net assets of €16.7 million one year earlier. Overall, we believe these results demonstrate both financial discipline and our ability to secure the capital required to execute on our strategy and create long-term shareholder value. Next slide please. Moving on to events after the reporting period. So, on the 1st of July, the board confirmed the grant of approximately 2.2 million options under the company's 2026 Share Option plan. These awards are intended to support employee retention and align incentives with long-term shareholder value creation. On the 3rd of August, the company approved the exercise of 3.6 million special rights. This was completed in connection with the scheduled amortization payment of the first and second tranche convertible bonds. As of August 20th, 2026, Faron Pharmaceuticals Oy had 227.8 million ordinary shares outstanding, of which 25 million shares were held in Treasury. So in summary, Faron Pharmaceuticals Oy enters the second half of 2026 with a strengthened capital position. Funding is secured through the key value-inflecting catalysts and a clear focus on delivering the next important clinical milestones for BEXERA.

Juho Jalkanen
15:28 - 16:25

Thank you. Juho Jalkanen. Then to some key conclusions before Q&A. Next slide please. So we just want to recap, first of all, a large underserved market opportunity in high-risk myelodysplastic syndromes with best-in-class efficacy seen to date, with actually one of the worst or most severe populations reported. And this is thanks to our unique, differentiated mode of action and safety profile, which is exactly what these patients need. This gives us an open window to be the leading asset in development for high-risk myelodysplastic syndrome. And we are funded to deliver the next significant catalyst. Thank you. Next slide and questions, please.

Unknown 1
16:30 - 16:46

Thank you for the excellent presentation. Let's go for the first question. BEXERA hasn't started yet. What is actually left to do before the first patient is in? And are you still confident to have the first patient in this year?

Juho Jalkanen
16:47 - 17:09

We are very confident we are well on track. We have completed country and site selection and feasibility, and regulatory submissions to the regions being USA, Europe and UK have been submitted. So we are very well on track to deliver the first patient in.

Unknown 1
17:12 - 17:22

Thank you. And as a follow-up question for that, is there something that you can tell us about enrollment or expectations for enrollment?

Juho Jalkanen
17:24 - 17:41

Again, we expect enrollment to be completed around the beginning of August, allowing for the CRs to mature so that we will be doing the data cut and readout for November 2027.

Unknown 1
17:43 - 17:52

Thank you. Then for the next question. What are the actual go or no-go milestones for BEXERA that investors should track?

Juho Jalkanen
17:54 - 19:15

So BEXERA itself is a very compact, straightforward study. So there will be no interim. It is the actual readout that will be coming in late 2027 for that readout to look out for, and no-go/go decisions are based on the primary endpoint. The complete response (CR) readout will give us insight into the effect size. How big is the effect size against the comparator single-agent azacitidine? So the most important information from that will be the size of the phase three. Then, also very importantly, will be confirming the phase three endpoint with the FDA at that moment, and also depending on the effect size again. How high is our CR rate compared to the control CR rate? Is the question whether, for relapsed/refractory myelodysplastic syndrome in the last-line population, which has no options available, accelerated approval should be considered in that area. But that's a separate discussion to be had with the FDA.

Unknown 1
19:18 - 19:26

Thank you. With Parexel now on board, does that change the cost or timeline of BEXERA?

Juho Jalkanen
19:28 - 19:56

It does not change the cost. Actually, I cannot elaborate too much, but we have a risk-sharing based agreement where with a certain amount of money, we are aiming to hit the enrollment and readout. So we are, in a sense, capping it. And again, with a large global organization like Parexel, we believe in fast and strong delivery. So again, we will be on time and on cost.

Unknown 1
19:59 - 20:10

Thank you. Your cash runway guidance is until Q4 next year. What assumptions sit behind that and what would move it?

Heikki Jouttijärvi
20:12 - 20:14

Yes. So, I guess one question.

Juho Jalkanen
20:14 - 20:14

Is.

Heikki Jouttijärvi
20:15 - 20:52

Based on the current forecast of management of our clinical trial expenditure. So principally our BEXERA costs, our operating costs, and the expected timing of the cash flows. And it is good to know that our cash runway does not assume any additional cash flow from new financing, income from potential partnerships, or related milestone payments. Faster than planned BEXERA enrollment, unplanned investigator-initiated trial (IIT) support, or non-dilutive income, for example from a partnership, are examples of factors that could impact the cash runway.

Unknown 1
20:56 - 21:09

Thank you. Then the next one, G&A expenses fell. Was this a result of a cost savings program and tight budget control, or where did this reduction come from?

Heikki Jouttijärvi
21:11 - 21:31

The first half of 2025 was impacted by 1.3 million in non-recurring consulting costs related to our convertible bonds. But beyond that, we've maintained discipline on our overall costs and our G&A spend in general, and we haven't announced a formal named restructuring or saving plan.

Unknown 1
21:34 - 21:56

Thank you. The BEXMAB frontline data shows an 85% response rate. An 85% response rate. 35% complete remission rate and 16 months of duration for complete response. Why should investors trust that this holds up in a randomized trial?

Juho Jalkanen
22:00 - 23:13

As a physician scientist, what is very convincing to us and our investigators is what we see happen in the bone marrow of these patients. So again, not just killing cancer, but actually enhancing the production of healthy blood cells. The majority of these patients are becoming transfusion independent. The majority of these patients are achieving MRD negativity. So, no minimal residual disease. No disease to be measured. Blood counts return to normal. It is very convincing, but the most convincing aspect, as we and our investigators believe, is the last-line efficacy and the last-line survival benefit. It is some of the strongest data seen in this space, and not that many of these drugs that have been trialed in high-risk myelodysplastic syndrome actually had such good late-line results. So the last-line results are actually what stand out here.

Unknown 1
23:15 - 23:27

Thank you. How many patients have now been dosed with bexmarilimab in total. And does that population size support the safety profile?

Juho Jalkanen
23:29 - 23:53

Yes, it does, actually. So almost 300 patients have now been dosed with bexmarilimab. And the safety profile is very robust and solid. No surprises. It is constantly giving the same signal. So we are very happy with the safety profile. And again, close to 300 patients have been treated with the drug already.

Unknown 1
23:58 - 24:07

Thank you. What is the actual financial exposure to the Investigator-Initiated Trials (IIT) portfolio compared to BEXERA?

Juho Jalkanen
24:09 - 24:26

It is actually very minimal. So the vast majority of our finances goes to the myelodysplastic syndrome program, the lead program to give a ballpark. Basically, these trials take one tenth of what an actual sponsored trial takes.

Unknown 1
24:28 - 24:39

Thank you. Then, one final question. What complete remission delta over azacitidine alone would you consider as a clear win?

Juho Jalkanen
24:41 - 25:13

A 10% improvement. So based on the current data, what we would like to see, and which would be amazing, is that we double the CR rate, but that would be absolutely amazing. But that's what we're aiming for. But we will be very happy. And again, the go/no-go decision is if we improve the CR rate by 10%. So, let's say if azacitidine is 16%, we are at 26%; if azacitidine is 18%, we are at 28%.

Unknown 1
25:16 - 25:20

Thank you. That was the final question.

Juho Jalkanen
25:23 - 25:39

Thank you everybody. Thank you for joining the H1 webcast. We look forward to keeping you up to date on our progress. And again, data generation starts from here. Exciting times ahead. Have a good day.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…